TYK MEDICINES-B Shares Surge Over 7% Following Annual Report and Key AACR Presentation Announcement

Stock News04-01

TYK MEDICINES-B (02410) saw its shares rise more than 7%. As of the time of writing, the stock was up 7.07%, trading at HKD 10.9 with a turnover of HKD 30.54 million.

On March 31, TYK MEDICINES-B released its annual results for the period ending December 31, 2025. The company reported R&D costs of approximately RMB 244 million, a year-on-year increase of 3.7%. Other income and gains amounted to RMB 37.609 million, up 23.14% compared to the previous year. During the reporting period, other income and gains primarily included government grants related to revenue, government grants associated with interest-free financing, and gains from the sale of a subsidiary.

Notably, TYK MEDICINES-B announced that it will present research progress and findings for five innovative drug candidates at the poster session of the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased are TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five are self-developed small-molecule anti-tumor innovative drug candidates.

The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22 in San Diego, USA. The company's posters will be presented on April 19, April 20, and April 21.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153741167?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 12:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153741167","market":"sh","top_or_hot":-1,"title":"TYK MEDICINES-B Shares Surge Over 7% Following Annual Report and Key AACR Presentation Announcement","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) saw its shares rise more than 7%. As of the time of writing, the stock was up 7.07%, trading at HKD 10.9 with a turnover of HKD 30.54 million.</p>\n<p>On March 31, TYK MEDICINES-B released its annual results for the period ending December 31, 2025. The company reported R&D costs of approximately RMB 244 million, a year-on-year increase of 3.7%. Other income and gains amounted to RMB 37.609 million, up 23.14% compared to the previous year. During the reporting period, other income and gains primarily included government grants related to revenue, government grants associated with interest-free financing, and gains from the sale of a subsidiary.</p>\n<p>Notably, TYK MEDICINES-B announced that it will present research progress and findings for five innovative drug candidates at the poster session of the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased are TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five are self-developed small-molecule anti-tumor innovative drug candidates.</p>\n<p>The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22 in San Diego, USA. The company's posters will be presented on April 19, April 20, and April 21.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK MEDICINES-B Shares Surge Over 7% Following Annual Report and Key AACR Presentation Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK MEDICINES-B Shares Surge Over 7% Following Annual Report and Key AACR Presentation Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-01 12:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) saw its shares rise more than 7%. As of the time of writing, the stock was up 7.07%, trading at HKD 10.9 with a turnover of HKD 30.54 million.</p>\n<p>On March 31, TYK MEDICINES-B released its annual results for the period ending December 31, 2025. The company reported R&D costs of approximately RMB 244 million, a year-on-year increase of 3.7%. Other income and gains amounted to RMB 37.609 million, up 23.14% compared to the previous year. During the reporting period, other income and gains primarily included government grants related to revenue, government grants associated with interest-free financing, and gains from the sale of a subsidiary.</p>\n<p>Notably, TYK MEDICINES-B announced that it will present research progress and findings for five innovative drug candidates at the poster session of the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased are TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five are self-developed small-molecule anti-tumor innovative drug candidates.</p>\n<p>The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22 in San Diego, USA. The company's posters will be presented on April 19, April 20, and April 21.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"创新药","start_time":0,"source_url":"","article_id":"1153741167","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153741167","pubTimestamp":1775016153,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) saw its shares rise more than 7%. As of the time of writing, the stock was up 7.07%, trading at HKD 10.9 with a turnover of HKD 30.54 million. On March 31, TYK MEDICINES-B...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","159992":"创新药","09939":"开拓药业-B","BK4585":"ETF&股票定投概念","BK4588":"碎股","06978":"永泰生物-B","BK1515":"抗疫概念","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","BK1574":"生物医药B类股","02410":"同源康医药-B"},"translate_title":"TYK MEDICINES-B股在年度报告和AACR重要演示公告发布后飙升超过7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"159992":1,"VXUS":1,"02410":1,"06978":1,"09939":1},"content_text":"TYK MEDICINES-B (02410) saw its shares rise more than 7%. As of the time of writing, the stock was up 7.07%, trading at HKD 10.9 with a turnover of HKD 30.54 million.\nOn March 31, TYK MEDICINES-B released its annual results for the period ending December 31, 2025. The company reported R&D costs of approximately RMB 244 million, a year-on-year increase of 3.7%. Other income and gains amounted to RMB 37.609 million, up 23.14% compared to the previous year. During the reporting period, other income and gains primarily included government grants related to revenue, government grants associated with interest-free financing, and gains from the sale of a subsidiary.\nNotably, TYK MEDICINES-B announced that it will present research progress and findings for five innovative drug candidates at the poster session of the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased are TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five are self-developed small-molecule anti-tumor innovative drug candidates.\nThe 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22 in San Diego, USA. The company's posters will be presented on April 19, April 20, and April 21.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153741167","isCrawlerRequest":true}